Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|February 26, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016
- Volume 11
- Issue 3
Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trials
Author(s)Pharmaceutical Technology Editors
Cirrus Pharmaceuticals will launch services for manufacturing cGMP materials for early-phase clinical trials at its Raleigh-Durham, NC facility.
Advertisement
Cirrus Pharmaceuticals, a Kemwell Company, has announced that it is ready to launch services for manufacturing cGMP materials for early-phase clinical trials in a new suite at its Raleigh-Durham, NC site.
The company offers development and manufacturing capabilities for niche dosage forms. The company will manufacture metered dose inhalers (MDI) on its Pamasol pressure filling line in batch sizes up to 25L. One- and two-step filling as well as cold filling for suspension and solution MDIs will be offered.
Other services include dry powder filling in capsules for dry powder inhalers, and manufacture of nasal solutions, suspensions, and powders. Clinical manufacturing of other dosage forms that will be offered from the site are topicals, oral solids, and oral liquids.
Source: C
Articles in this issue
over 10 years ago
Small-Scale Modeling Boosts Downstream Developmentover 10 years ago
Technologies Expand Horizons of the Analytical Labover 10 years ago
Global Conflicts and CMO Impactsover 10 years ago
Hazardous Reagents for Higher Yieldsover 10 years ago
Mechanical Pipettes Have Ergonomic Designover 10 years ago
Benchtop Centrifuge Features Hybrid Rotorover 10 years ago
ICIG Acquires Sandoz Site in Germanyover 10 years ago
Recipharm Acquires Italian CDMOover 10 years ago
Patheon Signs Strategic Agreement with GrünenthalAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement